Exenatide
GLP-1 Receptor AgonistapprovedAlso known as: Byetta, Bydureon, Exendin-4, AC2993
The first GLP-1 receptor agonist approved for type 2 diabetes, originally derived from Gila monster venom, available in twice-daily and once-weekly formulations.
Overview
Exenatide is a synthetic version of exendin-4, a 39-amino acid peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). It was the first GLP-1 receptor agonist approved by the FDA (2005) for type 2 diabetes, pioneering an entirely new drug class. Exenatide shares approximately 53% homology with human GLP-1 but is resistant to DPP-4 degradation, giving it a much longer duration of action. Available as Byetta (twice-daily) and Bydureon (once-weekly extended-release microsphere formulation), exenatide effectively lowers blood glucose and promotes moderate weight loss. While it has been largely eclipsed by newer GLP-1 RAs like semaglutide and tirzepatide, exenatide remains historically significant and is still widely prescribed.
Mechanism of Action
Exenatide activates the GLP-1 receptor with similar potency to native GLP-1 but with greatly extended duration due to resistance to DPP-4 cleavage. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic signaling. The extended-release Bydureon formulation uses poly(D,L-lactide-co-glycolide) microspheres that slowly release exenatide over weeks. Exenatide also promotes beta-cell proliferation and reduces beta-cell apoptosis in preclinical models.
Molecular Formula
C184H282N50O60S
Molecular Weight
4186.6 g/mol
Sequence
His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Dosage Protocols
Dose Range
5mcg – 10mcg
Frequency
Twice daily
Route
subcutaneous
Cycle Length
Ongoing / chronic
Start at 5mcg twice daily within 60 minutes before morning and evening meals. May increase to 10mcg twice daily after 1 month.
Source: FDA prescribing information (Byetta)
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
2mg extended-release vial or 10mcg/dose pen
Last Updated
2026-02
Brand Byetta/Bydureon (AstraZeneca). List ~$800/mo. Generic/biosimilar availability improving. GLP-1 for T2D.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Nausea | moderate |
| Vomiting | moderate |
| Diarrhea | mild |
| Injection site nodule | mild |
| Headache | mild |
| Pancreatitis | severe |
| Hypoglycemia | moderate |
Pros & Cons
First-in-class GLP-1 RA with the longest post-marketing safety track record (since 2005)
Available in both twice-daily and once-weekly formulations for flexibility
Effective blood glucose lowering with moderate weight loss (2-4 kg)
Demonstrated beta-cell protective effects in preclinical studies
Higher nausea rates than many newer GLP-1 RAs, especially the twice-daily formulation
Less weight loss and HbA1c reduction compared to semaglutide and tirzepatide
Bydureon requires reconstitution and can cause injection site nodules
No dedicated cardiovascular outcome trial showing MACE reduction (EXSCEL showed non-inferiority only)
Research Studies
🩸 Blood Work
HbA1c
Baseline blood sugar — GLP-1 therapy standard
Fasting Blood Glucose
Hypoglycemia monitoring
Kidney Function (BMP/CMP)
Exenatide is renally cleared — kidney function critical
Lipid Panel
Baseline metabolic markers
Pancreatic Enzymes (Lipase/Amylase)
Higher pancreatitis risk compared to other GLP-1s
FDA-approved GLP-1 (Byetta/Bydureon). Contraindicated in severe renal impairment (CrCl <30). Kidney function is especially critical for this GLP-1.
Legal Status
FDA-approved (Byetta 2005, Bydureon 2012). Prescription-only. EMA-approved. Available globally for type 2 diabetes.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Collagen Peptides
Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.